Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases

Bruni, Cosimo; Cigolini, Cosimo; Tesei, Giulia; Cometi, Laura; Bartoli, Francesca; Fiori, Ginevra; Nacci, Francesca; Randone, Silvia Bellando; Guiducci, Serena; Cerinic, Marco Matucci

doi:10.5152/eurjrheum.2020.21162

Cited by 3 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Successful experiences with DTT in patients with PsA and severe atopic dermatitis with secukinumab and dupilumab was also reported, without significant AEs ( 54 ). In a case series of 28 patients with rheumatic diseases treated with denosumab and biological therapy, a comparable safety was shown between control group compared with biological monotherapy ( 55 ).…”

Section: Discussionmentioning

confidence: 99%

Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

Valero-Martínez,

Urgelles,

Sallés

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. This is a retrospective, real-world multicenter study in refractory SpA and PsA patients with simultaneous use of two biological or synthetic targeted agents. Effectiveness was assessed using Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Disease Activity in Psoriatic Arthritis (DAPSA) Score. We identified 39 different DTT combinations in 36 patients (22 SpA; 14 PsA), 25 of them with concomitant inflammatory bowel disease. The most commonly used combinations were TNF inhibitor plus antagonist of the IL12/23 pathway, followed by TNF inhibitor plus IL-17 antagonist. During a median exposure of 14.86 months (IQR 8-20.2), DTT retention rate was 69.4% (n=25/36; 19 SpA, 6 PsA). Major clinical improvement (change in ASDAS-CRP > 2 or improvement > 85% in DAPSA) was achieved in 69.4% of patients (n=25/36 therapeutical combinations; 17/21 SpA, 8/15 PsA), with a 58.3% (n=21/36 combinations; 15/20 SpA, 6/13 PsA) low-activity/remission rate. Of the patients who were receiving glucocorticoids, 55% managed to withdraw them during follow-up. Interestingly, only four serious adverse events in three patients were observed, leading to DTT discontinuation.

show abstract

Section: Discussionmentioning

confidence: 99%